Zoledronic Acid
Zoledronate infusions every 5 years may lower fracture risk for early postmenopausal women
Early postmenopausal women who receive zoledronate every 5 years have a lower risk for morphometric vertebral fractures than those receiving placebo, according to trial findings published in The New England Journal of Medicine.
Most providers start osteoporosis therapy without full assessment of secondary causes
NEW ORLEANS —Few providers conduct a complete assessment of secondary causes of osteoporosis before initiating medication, according to findings presented at the AACE annual meeting.
Most providers start osteoporosis therapy without full assessment of secondary causes
NEW ORLEANS —Few providers conduct a complete assessment of secondary causes of osteoporosis before initiating medication, according to findings presented at the AACE annual meeting.
Fracture liaison services, zoledronic acid infusion improved osteoporosis treatment rates
Published results showed integration of fracture liaison and orthopedic services, as well as inpatient zoledronic acid administration, may improve osteoporosis pharmacotherapy rates among patients with fragility fractures.
Bisphosphonates, denosumab recommended to treat adults with hypercalcemia of malignancy
A new clinical practice guideline from the Endocrine Society recommends treatment with IV bisphosphonates or denosumab in addition to adequate hydration for adults with moderate hypercalcemia of malignancy.
Zoledronic acid provides protection against bone loss after acute spinal cord injury
An annual infusion of zoledronic acid can help attenuate bone loss in adults with acute spinal cord injury, according to a study published in the Journal of Bone and Mineral Research.
Denosumab increasingly prescribed in osteoporosis treatment
The use of denosumab to treat osteoporosis has increased rapidly since its FDA approval in 2010, and it is now the second most used medication after alendronate, according to data presented at the ENDO annual meeting.
Zoledronic acid maintains BMD gains after teriparatide, denosumab combination therapy
Following short-term therapy with teriparatide plus denosumab with a single dose of zoledronic acid may prevent bone loss associated with denosumab cessation among postmenopausal women, according to a study published in the Journal of Bone and Mineral Research.
Frequent zoledronic acid use, other factors increase risk for osteonecrosis of the jaw
Patients with cancer who received zoledronic acid for metastatic bone disease appeared at higher risk for osteonecrosis of the jaw if they had more frequent exposure to the agent, poor oral health or currently smoked, study results showed.
Top in endocrinology: Circadian rhythm, zoledronic acid and AF risk
The top five stories in endocrinology last week were all based on presentations from the American Society for Bone and Mineral Research virtual meeting.